Trials / Completed
CompletedNCT00151996
Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase II, Open-Label Co-Administration Study of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of administering SPD503 (Guanfacine hydrochloride) with psychostimulants (amphetamine or methylphenidate) for treatment of ADHD in children and adolescents aged 6-17
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylphenidate + SPD503 (Guanfacine hydrochloride) | |
| DRUG | Amphetamine + SPD503 |
Timeline
- Start date
- 2004-08-16
- Primary completion
- 2004-12-27
- Completion
- 2004-12-27
- First posted
- 2005-09-09
- Last updated
- 2021-06-10
- Results posted
- 2009-11-26
Source: ClinicalTrials.gov record NCT00151996. Inclusion in this directory is not an endorsement.